(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.35%) $91.45
1.81% $ 48.36
@ $42.61
Emitido: 14 feb 2024 @ 14:47
Retorno: 13.49%
Señal anterior: feb 13 - 15:34
Señal anterior:
Retorno: 1.44 %
Live Chart Being Loaded With Signals
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1...
Stats | |
---|---|
Volumen de hoy | 286 201 |
Volumen promedio | 637 417 |
Capitalización de mercado | 2.80B |
EPS | $-1.040 ( 2024-05-02 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -16.12 |
ATR14 | $0.0570 (0.12%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-12-19 | Shuman Harry | Sell | 115 | Common Shares |
2023-12-15 | Silverman Peter B. | Buy | 1 286 | Common Shares |
2023-12-15 | Silverman Peter B. | Buy | 21 100 | Common Shares |
2023-12-15 | Silverman Peter B. | Sell | 21 100 | Share Option (right to buy) |
2023-12-15 | Silverman Peter B. | Sell | 22 386 | Common Shares |
INSIDER POWER |
---|
69.18 |
Last 99 transactions |
Buy: 2 523 001 | Sell: 3 636 553 |
Volumen Correlación
Merus NV Correlación
10 Correlaciones Más Positivas | |
---|---|
HOWL | 0.948 |
YMAB | 0.946 |
CGEM | 0.943 |
SLN | 0.941 |
NVCN | 0.937 |
REYN | 0.935 |
KYMR | 0.934 |
BRIVU | 0.931 |
PPH | 0.929 |
VERA | 0.929 |
10 Correlaciones Más Negativas | |
---|---|
WINT | -0.939 |
REVB | -0.937 |
VALN | -0.937 |
BIOL | -0.933 |
SRNGW | -0.933 |
VRM | -0.931 |
LHDX | -0.931 |
SGML | -0.93 |
TENX | -0.928 |
IMV | -0.924 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Merus NV Correlación - Moneda/Commodity
Merus NV Finanzas
Annual | 2023 |
Ingresos: | $43.95M |
Beneficio Bruto: | $-83.46M (-189.91 %) |
EPS: | $-3.00 |
FY | 2023 |
Ingresos: | $43.95M |
Beneficio Bruto: | $-83.46M (-189.91 %) |
EPS: | $-3.00 |
FY | 2022 |
Ingresos: | $41.59M |
Beneficio Bruto: | $29.60M (71.19 %) |
EPS: | $-2.92 |
FY | 2021 |
Ingresos: | $49.11M |
Beneficio Bruto: | $0.00 (0.00 %) |
EPS: | $-1.730 |
Financial Reports:
No articles found.
Merus NV
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico